Ondine Biomedical Inc.
OBIMF
$0.25
$0.0847.06%
OTC PK
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 585.70K | 592.80K | 366.10K | 352.90K | 425.10K |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 585.70K | 592.80K | 366.10K | 352.90K | 425.10K |
| Cost of Revenue | 243.20K | 246.10K | 128.70K | 124.00K | 142.20K |
| Gross Profit | 342.50K | 346.70K | 237.40K | 228.90K | 282.90K |
| SG&A Expenses | 1.76M | 1.78M | 1.78M | 1.72M | 2.22M |
| Depreciation & Amortization | 86.10K | 87.10K | 101.90K | 98.20K | 93.90K |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 6.84M | 6.93M | 4.89M | 4.71M | 4.57M |
| Operating Income | -6.26M | -6.33M | -4.52M | -4.36M | -4.15M |
| Income Before Tax | -6.08M | -6.16M | -4.54M | -4.38M | -4.05M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -6.08M | -6.16M | -4.54M | -4.38M | -4.05M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -6.08M | -6.16M | -4.54M | -4.38M | -4.05M |
| EBIT | -6.26M | -6.33M | -4.52M | -4.36M | -4.15M |
| EBITDA | -6.21M | -6.27M | -4.41M | -4.25M | -4.11M |
| EPS Basic | -0.01 | -0.01 | -0.01 | -0.01 | -0.01 |
| Normalized Basic EPS | -0.01 | -0.01 | -0.01 | -0.01 | -0.01 |
| EPS Diluted | -0.01 | -0.01 | -0.01 | -0.01 | -0.01 |
| Normalized Diluted EPS | -0.01 | -0.01 | -0.01 | -0.01 | -0.01 |
| Average Basic Shares Outstanding | 492.92M | 492.92M | 437.24M | 437.24M | 307.73M |
| Average Diluted Shares Outstanding | 492.92M | 492.92M | 437.24M | 437.24M | 307.73M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |